Dayvigo and Trazodone Interaction: What Clinicians and Patients Need to Know

Lemborexant (brand name Dayvigo) is a dual orexin receptor antagonist approved by the FDA in December 2019 for insomnia in adults. Trazodone is an FDA-approved antidepressant (Desyrel and other brands, plus a generic extended-release version) that is widely prescribed off-label for insomnia at lower doses. Neither drug's label lists the other as an absolute contraindication, but combining them puts two sedating drugs with overlapping half-lives into the same night, and that overlap is the real clinical question.

Why this pairing comes up often

Insomnia and depression frequently co-occur, and trazodone is one of the most commonly used off-label sleep aids in patients who are also being treated for depression or anxiety. Lemborexant, as a newer non-benzodiazepine hypnotic, is increasingly considered for patients whose insomnia persists despite an existing antidepressant regimen, or added alongside trazodone rather than replacing it. Either direction of prescribing creates a combination that is pharmacologically active on more than one axis, so it deserves a real answer rather than a blanket "avoid" or "fine."

Why lemborexant behaves differently than older sleep drugs

Older hypnotics such as zolpidem and benzodiazepines act broadly on GABA-A receptors. Lemborexant instead blocks orexin-1 and orexin-2 receptors, suppressing the wake-promoting signal rather than nonselectively depressing the CNS. That mechanistic difference does not remove the sedation-overlap risk with other sedating drugs, but it does change how the drug is cleared: lemborexant is described in its FDA labeling as a major CYP3A4 substrate, which is the reason its label carries specific warnings about interacting drugs that affect that enzyme.

The interaction has two separate mechanisms

Pharmacodynamic overlap (established). Lemborexant suppresses orexinergic arousal signaling. Trazodone produces sedation mainly through histamine H1 antagonism, 5-HT2A antagonism, and alpha-1 adrenergic blockade. These are different receptor systems, but the downstream effect for both is reduced CNS arousal. Combining two drugs that each independently reduce arousal is expected to produce at least an additive sedative effect, and this is the basis for the FDA's general caution about combining Dayvigo with any CNS depressant.

Trazodone's sedative effect typically peaks within one to two hours of a dose and its active drug and metabolites persist for several hours afterward; lemborexant has a longer elimination half-life, generally cited in the range of roughly 17 to 19 hours. Because lemborexant clears more slowly than standard-release trazodone, a patient who takes both drugs at bedtime can have measurable levels of both compounds well into the following morning. This is the pharmacologic basis for next-morning impairment concerns, independent of any metabolic interaction.

Pharmacokinetic overlap (plausible, not directly studied for this pair). Lemborexant is metabolized primarily by CYP3A4. Trazodone is also a CYP3A4 substrate and has been described in pharmacology references as a weak inhibitor of the enzyme at higher concentrations, an effect that would be expected to matter more at antidepressant doses (150 mg and above) than at typical insomnia doses (25 to 100 mg). No dedicated drug-drug interaction study of lemborexant plus trazodone appears in the FDA review materials available for this topic. The FDA's labeled interaction data for lemborexant come from studies with stronger CYP3A4 modulators (for example, itraconazole as a strong inhibitor), not from trazodone specifically. Any statement about how much trazodone raises lemborexant blood levels is an extrapolation from trazodone's general CYP3A4 profile, not a finding from a trial of the two drugs together, and should be treated as a hypothesis requiring pharmacist or literature verification before it is used to justify a specific dose decision.

This is the single most important sentence on this page: lemborexant and trazodone are not absolutely contraindicated together, their combined sedative effect is additive and well supported by each drug's individual pharmacology, but no published trial has directly measured the size of any pharmacokinetic interaction between them, so dosing decisions should rely on the FDA's general CNS-depressant guidance and clinical monitoring rather than on a specific numeric interaction estimate.

What the FDA label actually establishes

The current FDA-approved prescribing information for Dayvigo (lemborexant) instructs prescribers to consider dose adjustment of lemborexant, the other CNS depressant, or both, when the two are used together, and it warns that combining Dayvigo with other CNS depressants increases the risk of next-day psychomotor impairment, including impaired driving. Rather than reproduce exact label wording here, which should be checked against the current label directly, the practical guidance is: start at the lowest available lemborexant dose (5 mg) when a patient is already taking a sedating antidepressant like trazodone, and avoid adding a second sedating agent if the first one is already providing adequate sleep benefit on its own.

Strong CYP3A4 inhibitors, such as itraconazole, clarithromycin, and ritonavir-containing regimens, are absolutely contraindicated with lemborexant because they substantially raise lemborexant exposure. Trazodone does not belong to that strong-inhibitor category, so this absolute contraindication does not apply to the trazodone combination. The label's guidance for use with a CNS depressant that is not a strong or moderate CYP3A4 inhibitor is caution and dose management, not prohibition. (Source: current Dayvigo prescribing information, accessdata.fda.gov, verify against the most recent labeling update before citing a specific numeric threshold.)

Trazodone's pharmacology, briefly

Trazodone is FDA-approved for major depressive disorder; its use for insomnia at lower doses is off-label. At low doses (roughly 25 to 100 mg), sedative antihistamine and 5-HT2A effects dominate with limited serotonin reuptake inhibition. At doses of 150 mg and above, serotonin transporter inhibition becomes clinically relevant, which is why trazodone at antidepressant doses carries its own set of drug interaction considerations, separate from the lemborexant question. Lemborexant has no serotonergic mechanism, so the lemborexant-trazodone combination does not raise a serotonin syndrome concern; that risk would come from combining trazodone with other serotonergic drugs, not with lemborexant.

What the clinical trial evidence does and does not show

The phase 3 trials that supported lemborexant's approval evaluated the drug against placebo and against zolpidem in adults with insomnia disorder. Trials of this kind routinely exclude patients who are taking other CNS-active sedating medications, which is standard trial design for isolating a hypnotic's own effect, but it also means the pivotal trials do not directly characterize what happens when lemborexant is added on top of an existing trazodone regimen. Any efficacy figures from those trials (sleep-onset latency reductions, responder rates) describe lemborexant used alone and should not be assumed to transfer unchanged to a patient also taking trazodone. Readers who need the exact trial numbers should verify them against the primary publications rather than relying on a secondary summary, since several specific figures circulating in older summaries of this topic could not be confirmed here.

Monitoring when the combination is used

Daytime and next-morning sedation. Ask directly at the first follow-up visit, generally within two to four weeks of starting or changing either drug. Patients often do not volunteer drowsiness unless asked.

Driving and machinery operation. The Dayvigo label carries a specific warning about next-day impairment. Adding a second sedating drug is expected to increase, not decrease, this risk. Advise patients not to drive the morning after starting or increasing either medication until they know how they respond.

Fall risk in older adults. Sedative-hypnotics as a class are associated with increased fall risk in older adults; this is a well-established class effect rather than a number specific to the lemborexant-trazodone pair, and the size of any added risk from combining the two has not been separately quantified in the material available for this review.

Complex sleep behaviors. The lemborexant label carries a warning about sleepwalking, sleep-related eating, and similar parasomnias. Trazodone has isolated case reports of similar behaviors. The combination itself has not been formally studied for this outcome; the concern is theoretical and additive rather than quantified.

Hepatic function. Lemborexant exposure rises in patients with hepatic impairment, and the label recommends dose limitation in mild impairment and avoidance in moderate-to-severe impairment. Trazodone is also hepatically metabolized. A patient with liver disease on both drugs faces compounded, not merely additive, uncertainty about clearance, and this is a reasonable trigger for specialist or pharmacist consultation rather than routine dosing.

Evidence-status assessment for this interaction

Patient counseling points

Take both medications close to bedtime, not earlier in the evening, since taking them well before sleep extends the period during which peak sedation overlaps with waking hours the next morning. Avoid alcohol, which is also a CNS depressant and compounds sedation from both drugs. Contact the prescriber if morning grogginess lasts more than a couple of hours, if there is any sleepwalking or unusual nighttime behavior, or after any fall. Do not stop trazodone abruptly after prolonged use at antidepressant doses; discuss a taper with the prescriber, since abrupt discontinuation can cause withdrawal-type symptoms and rebound insomnia.

Special populations

Older adults. Sedative-hypnotics and trazodone are both flagged for cautious use in older adults in geriatric prescribing guidance because of sedation and fall risk. Combining two flagged agents warrants an explicit documented risk-benefit discussion rather than routine co-prescribing.

Pregnancy and breastfeeding. Neither drug is generally recommended during pregnancy or breastfeeding; individualized counseling with the prescribing clinician is appropriate, and this page does not substitute for that discussion.

Obstructive sleep apnea. Lemborexant labeling advises caution in patients with OSA. Adding a second sedating agent, such as trazodone, raises the same theoretical concern about upper-airway tone and should prompt caution until apnea is adequately managed.

Alternatives worth considering

Cognitive behavioral therapy for insomnia (CBT-I) is recommended as a first-line treatment for chronic insomnia by major clinical practice guidelines and poses no risk of drug interactions. If lemborexant is needed while continuing trazodone, suvorexant represents the alternative orexin receptor antagonist but similarly depends on CYP3A4 metabolism and carries comparable CNS depressant warnings, making it an unsuitable alternative for managing this drug combination. When antidepressant efficacy and sleep promotion are both therapeutic goals, mirtazapine demonstrates effectiveness for each but introduces distinct sedation-related and metabolic interaction considerations that warrant individual assessment.

What is established, what is plausible, and what is not known

Established: lemborexant and trazodone both cause CNS sedation through separate receptor systems, and the FDA label for Dayvigo instructs caution and possible dose reduction with any CNS depressant. Plausible but unproven: a clinically meaningful pharmacokinetic boost to lemborexant exposure from trazodone's weak CYP3A4 inhibition, particularly at antidepressant doses. Not established: any specific numeric estimate of increased fall risk, AUC change, or impairment duration unique to this drug pair. Readers and prescribers should treat this combination as a monitored, individualized decision rather than either an automatic green light or a prohibited pairing, and should verify any precise dosing or interaction figure against the current FDA label and pharmacy references before applying it to a specific patient.